000			01652 a2200457 4500
005			20250515050252.0
264		0	_c20070327
008			200703s 0 0 eng d
022			_a0090-8258
024	7		_a10.1016/j.ygyno.2006.10.019 _2doi
040			_aNLM _beng _cNLM
100	1		_aSeiden, M V
245	0	0	_aA phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. _h[electronic resource]
260			_bGynecologic oncology _cMar 2007
300			_a727-31 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCetuximab
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aErbB Receptors _xbiosynthesis
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMiddle Aged
650	0	4	_aOrganoplatinum Compounds _xpharmacology
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aPeritoneal Neoplasms _xdrug therapy
700	1		_aBurris, H A
700	1		_aMatulonis, U
700	1		_aHall, J B
700	1		_aArmstrong, D K
700	1		_aSpeyer, J
700	1		_aWeber, J D A
700	1		_aMuggia, F
773	0		_tGynecologic oncology _gvol. 104 _gno. 3 _gp. 727-31
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2006.10.019 _zAvailable from publisher's website
999			_c16698036 _d16698036